Start-up biotech Clovis Oncology has signed a $380 million deal to license an experimental pancreatic cancer drug from Norwegian company Clavis Pharma.
GenVec Receives Orphan Drug Designation, $22M Development Deal
GenVec’s experimental drug to treat pancreatic cancer has been granted orphan drug status by the U.S. Food and Drug Administration.
Melanoma Drug Called a “Breakthrough” After Study
Scientists are calling Plexxikon’s experimental skin cancer drug a “breakthrough” after it successfully shrank tumors in clinical trial patients.
